Fig. 1 · Structure

Documents & Downloads

Lovastatin

Cat. No. A11877 CAS 75330-75-5

HMG-CoA reductase inhibitor

Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HMG-CoA reductase (Cell-free assay) 3.4 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 11.4 μM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 23570542]
A549 IC50 19.8 μM Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis [PMID: 23570542]
HepG2 IC50 37 nM Concentration required to inhibit HMG-CoA reductase by 50% was determined in Hep G2 cell line [PMID: 1527791]
HepG2 IC50 50 nM Inhibition of cellular HMG-CoA reductase in cultures of human HEP G2 cells, determined by decreased incorporation of sodium [14C]acetate into cholesterol. [PMID: 2296036]
HepG2 IC50 8.3 μM Lipid lowering activity in human HepG2 cells assessed as decrease in oleic acid elicited lipid accumulation after 6 hrs by oil-red O staining method [PMID: 26169125]
HES IC50 13 nM Concentration required to inhibit HMG-CoA reductase by 50% was determined in HES 9 cell line [PMID: 1527791]
Hs68 IC50 23.2 μM Cytotoxicity against human HS68 cells after 72 hrs by MTT assay [PMID: 23570542]
HT-29 IC50 46.8 μM Growth inhibition of human HT29 cells after 96 hrs by MTS assay [PMID: 17472962]
KB IC50 15.6 μM Cytotoxicity against human KB cells by resazurin microplate assay [PMID: 27228159]
LS180 IC50 25.3 μM Growth inhibition of human LS180 cells after 96 hrs by MTS assay [PMID: 17472962]
MCF7 IC50 > 40 μM Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay [PMID: 27756564]
MDA-MB-231 IC50 > 40 μM Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay [PMID: 27756564]
MEF IC50 35 μM Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay [PMID: 23570542]
PC-3 IC50 5.4 μM Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay [PMID: 27756564]
SW480 IC50 7.1 μM Growth inhibition of human SW480 cells after 96 hrs by MTS assay [PMID: 17472962]
T47D IC50 > 40 μM Cytotoxicity against human T47D cells assessed as growth inhibition after 24 to 48 hrs by MTT assay [PMID: 27756564]
THP-1 IC50 8 μg/mL Inhibition of sICAM1/LFA1 interaction-mediated human THP1 cell adhesion after 1 hr by ELISA [PMID: 18672369]

17 records · Scroll to view more

Lovastatin Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Lovastatin from 4 published references. In vitro models include MDAMB468; BC3.

Lovastatin In Vitro Studies

In MDAMB468 cells, Lovastatin lactone had a cell proliferation IC50 of 9 μg/mL after 48 hours. Lovastatin treatment produced time-dependent ERK activation in BC3 and BCBL1 cells. In HUVECs, Lovastatin treatment was associated with both downregulated and upregulated genes. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell proliferation response in MDAMB468 cells

Cell-based study · MDAMB468 [1]

MDAMB468 cells were treated with lovastatin lactone for 48 hours. The cell proliferation IC50 was 9 μg/mL.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell proliferationIC50 9 μg/mL[1]

Literature-Reported Treatment Conditions

Exposure duration
48 hours
Reported limits
Not stated in the sentences used: dose, route, vehicle.
Methods and source locations

Compound reported in the paper: Lovastatin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > MTT assay (S12, S13); Results > Lovastatin inhibits cell proliferation (S88); Figure 1 legend (S140, S142)

Cell proliferation: Cell proliferation; comparator: control cells — Results > Lovastatin inhibits cell proliferation (S88); Figure 1 legend (S140)

Time-dependent ERK activation in BC3 and BCBL1 cells

Cell-based study · BC3 [2]

BC3 cells were treated with 30 μM Lovastatin, and phosphorylated ERK was evaluated by western blotting. Time-dependent ERK activation was reported in both BC3 and BCBL1 cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ERK1/2 (pERK) was evaluated by western blottingReported result it activated ERK1/2 in both BC3 and BCBL1 cells, in a time‐dependent fashion[2]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM
Exposure duration
for 24 and 48 h
Method
treated
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Lovastatin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

EXPERIMENTAL PROCEDURES > Cell culture, reagents and treatments (S7); RESULTS > Lovastatin activates ERK1/2 by reducing STAT3 tyrosine phosphorylation in PEL cells (S48); FIGURE 2 legend (S90)

ERK1/2 (pERK) was evaluated by western blotting: ERK1/2 (pERK) was evaluated by western blotting; comparator: not (CT) — RESULTS > Lovastatin activates ERK1/2 by reducing STAT3 tyrosine phosphorylation in PEL cells (S48); FIGURE 2 legend (S90)

Gene expression changes in HUVECs

Cell-based study · HUVECs [3]

HUVECs were treated with 0.5 µM Lovastatin. After 2 h, 12 genes were downregulated and 178 genes were upregulated; after 24 h, 33 genes were downregulated and 77 genes were upregulated.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
gene expression profiledifferential gene expression 12 genes were downregulated and 178 genes were upregulated; 33 genes were downregulated and 77 genes were upregulated[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 µM
Exposure duration
2 and 24 h of treatment
Vehicle
0.1% dimethyl sulfoxide
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Lovastatin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Untitled > Cell culture (S9); Materials and methods > Untitled > cDNA microarray (S20); Results > Untitled > Effects of lovastatin on the gene expression profile of HUVECs (S59, S61, S62)

gene expression profile: gene expression profile; comparator: vehicle-treated group — Results > Untitled > Effects of lovastatin on the gene expression profile of HUVECs (S59, S61, S62)

Lovastatin In Vivo Studies

Male WT mice with HFpEF received Lovastatin at 4 mg/kg/day in a design including HFD and AngII treatments. Lovastatin improved diastolic function compared with vehicle-treated HFpEF mice. [4]

Diastolic function in HFpEF mice

Animal study · male WT mice; HFpEF; N = 13 (HFpEF and HFpEF + lovastatin) [4]

Male WT mice with HFpEF received Lovastatin at 4 mg/kg/day in a design including HFD and AngII treatments. Lovastatin improved diastolic function compared with vehicle-treated HFpEF mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
diastolic functionReported result Lovastatin improves diastolic function in HFpEF mice[4]

Conditions shared by the study groups

Treatment course
one week prior to HFD plus AngII treatments for another 12 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lovastatin 4 mg/kg/dayvehicle-treated HFpEF miceLovastatin improves diastolic function in HFpEF mice[4]
Lovastatin 4 mg/kg/day
Model: male WT mice; HFpEF; N = 13 (HFpEF and HFpEF + lovastatin)
Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Lovastatin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Lovastatin ameliorates HFpEF phenotypes and increases endocardial circRNA-RBCK1 expression in mice (S97, S104); Methods > Animals and induction of a ‘two-hit’ model of HFpEF (S173); Methods > Conventional echocardiography (ECG) and doppler imaging (S180); Methods > Animal experimental protocols (S204); Fig. 6 legend (S374)

diastolic function: diastolic function; comparator: vehicle-treated HFpEF mice — Methods > Conventional echocardiography (ECG) and doppler imaging (S180); Fig. 6 legend (S374)

Lovastatin 4 mg/kg/day · Methods > Animal experimental protocols (S204); Fig. 6 legend (S374)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 75330-75-5
Applications HMG-CoA reductase inhibitor
Formula C24H36O5
Molecular Weight 404.54
Synonyms Mevacor
SMILES
CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 7 mg/mL (17.3 mM)
Water Insoluble
Ethanol 5 mg/mL (12.36 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2.3 mg/mL
Vehicle
5% DMSO+40%PEG 300+ 5% Tween80 + 50% ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Lovastatin Research References

  1. [1] Klawitter J, Shokati T, Moll V, et al. Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res (2010). PMID: 20205716 DOI: 10.1186/bcr2485 Source material
  2. [2] Santarelli R, Pompili C, Gilardini Montani MS, et al. Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21. IUBMB Life (2021). PMID: 33987937 DOI: 10.1002/iub.2503 Source material
  3. [3] Chu W, Guan L, Huang D, et al. Lovastatin exerts protective effects on endothelial cells via upregulation of PTK2B. Exp Ther Med (2016). PMID: 27602089 DOI: 10.3892/etm.2016.3547 Source material
  4. [4] Li B, Bai WW, Guo T, et al. Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1. Nat Commun (2024). PMID: 38580662 DOI: 10.1038/s41467-024-47327-z Source material

Added to your cart

View Cart Checkout
Loading...